Home › Funds › NAN FUNG TRINITY (HK) Ltd › VOR
NAN FUNG TRINITY (HK) Ltd position in VOR
VOR BIOPHARMA INC · Health Care
NAN FUNG TRINITY (HK) Ltd reported holding 721,550 shares of VOR (VOR BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$13.8M, representing 1.32% of its reported portfolio and ranking #30 among its reported holdings. NAN FUNG TRINITY (HK) Ltd has disclosed VOR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NAN FUNG TRINITY (HK) Ltd's VOR position evolved
NAN FUNG TRINITY (HK) Ltd first disclosed a stake in VOR in Q2 2026 at 646,550 shares (US$11.9M). The position peaked in Q3 2026 at 721,550 shares, worth US$13.8M. Across 2 filings, NAN FUNG TRINITY (HK) Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 721,550 shares valued at US$13.8M — an increase of 75,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 646.55K | $11.90M | New |
| Q3 2026 | 721.55K | $13.77M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VOR and 13F data
VOR (VOR BIOPHARMA INC) is a Health Care company. 75 other funds we track also report a position in VOR — the largest reported positions include TCG Crossover Management, LLC (US$104.4M), FCPM III SERVICES B.V. (US$75.8M), Venrock Adviser, LLC (US$56.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VOR
- TCG Crossover Management, LLC 5.67M sh · $104.44M · Q2 2026
- FCPM III SERVICES B.V. 4.12M sh · $75.80M · Q2 2026
- Venrock Adviser, LLC 3.04M sh · $56.00M · Q2 2026
- Frazier Life Sciences Management, L.P. 2.54M sh · $46.83M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $44.22M · Q2 2026
- Caligan Partners LP 1.93M sh · $35.44M · Q2 2026
- Paradigm Biocapital Advisors LP 1.75M sh · $32.22M · Q2 2026
- GREAT POINT PARTNERS LLC 1.70M sh · $31.30M · Q2 2026
- Nantahala Capital Management, LLC 845.00K sh · $15.56M · Q2 2026
- ADAR1 Capital Management, LLC 680.63K sh · $12.53M · Q2 2026
- Logos Global Management LP 650.00K sh · $11.97M · Q2 2026
- Rosalind Advisors, Inc. 648.60K sh · $11.94M · Q2 2026
More on NAN FUNG TRINITY (HK) Ltd
FAQ
How long has NAN FUNG TRINITY (HK) Ltd held VOR?
NAN FUNG TRINITY (HK) Ltd has disclosed VOR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is NAN FUNG TRINITY (HK) Ltd's current position in VOR?
As of Q3 2026, NAN FUNG TRINITY (HK) Ltd holds 721.55K shares of VOR (VOR BIOPHARMA INC), valued at $13.77M, representing 1.32% of its reported portfolio and ranking #30.
Has NAN FUNG TRINITY (HK) Ltd been buying or selling VOR?
In the latest 13F filing (Q3 2026), NAN FUNG TRINITY (HK) Ltd increased its position in VOR. The position peaked in Q3 2026 at 721.55K shares.
Which other funds hold VOR?
Other major institutional holders of VOR include TCG Crossover Management, LLC, FCPM III SERVICES B.V., Venrock Adviser, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.